Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NCX1022 is a NO-releasing derivative of Hydrocortisone. It is the most widely used anti-inflammatory drug for the treatment of skin inflammation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | NCX1022 is a NO-releasing derivative of Hydrocortisone. It is the most widely used anti-inflammatory drug for the treatment of skin inflammation. |
In vivo | NCX1022 is obviously more effective than Hydrocortisone in reducing contact dermatitis-induced leukocyte adhesion, particularly at the early time points. NCX1022, but not Hydrocortisone, obviously inhibits granulocyte recruitment. Topical pre- and post-treatment with NCX1022 (3 nmol) in C57BL6 mice not only reduces ear oedema formation in a dose-dependent manner but also is significantly more effective than the parent compound during the initial stages of inflammation (from 1 to 5 h). Post-treatment with Hydrocortisone does not modify the increased granulocyte infiltration induced by benzalkonium application, but NCX1022 reduces by 63% the myeloperoxidase (MPO) activity, producing a maximum effect at the dose of 3 nmol per ear. Histological samples of mouse ears treated with NCX1022 display a significant reduction in both the number of infiltrated cells and disruption of the tissue architecture compared to Hydrocortisone-treated tissues . |
Molecular Weight | 541.59 |
Formula | C29H35NO9 |
CAS No. | 571186-50-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NCX1022 571186-50-0 Others NCX 1022 NCX-1022 inhibitor inhibit